EQL Pharma out-license Mellozzan to a leading European Company in ADHD
EQL Pharma has today entered into an exclusive out-licensing agreement with a leading European Company in ADHD for EQL's proprietary product Mellozzan (melatonin) for Germany, the United Kingdom, Austria, Switzerland, Finland, Denmark and Norway. The agreement applies to tablets in six different strengths as well as an oral solution, where the latter is newly developed and ready to be sent to authorities for registration.Mellozzan is a medicine given to children with sleep disorders who have ADHD and where sleep hygiene measures are not enough. It can also be given as a short-term treatment